Cannabis affects people differently: Inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: A functional magnetic resonance imaging study with healthy volunteers

Psychological Medicine

Volumn 43, Issue 6, 2013, Pages 1255-1267

  Atakan, Z ^a   Bhattacharyya, S ^a   Allen, P ^a   Martin Santos R ^b   Crippa, J A ^c   Borgwardt, S J ^d   Fusar Poli, P ^a   Seal, M ^e   Sallis, H ^a   Stahl, D ^a   Zuardi, A W ^c   Rubia, K ^a   McGuire, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Cerebellum; fmri; middle temporal gyri; parahippocampus; response inhibition; Thc

Indexed keywords

DRONABINOL; PSYCHEDELIC AGENT;

ADULT; ARTICLE; BRAIN; CEREBELLUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FUNCTIONAL NEUROIMAGING; HUMAN; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAHIPPOCAMPAL GYRUS; PATHOPHYSIOLOGY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; TEMPORAL LOBE; YOUNG ADULT; DRUG EFFECTS; PSYCHOSES, SUBSTANCE-INDUCED;

ADULT; BRAIN; CEREBELLUM; DOUBLE-BLIND METHOD; DRONABINOL; FUNCTIONAL NEUROIMAGING; HALLUCINOGENS; HEALTHY VOLUNTEERS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PARAHIPPOCAMPAL GYRUS; PSYCHOSES, SUBSTANCE-INDUCED; TEMPORAL LOBE; YOUNG ADULT;

EID: 84877787435     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291712001924     Document Type: Article

References (68)

1. Arseneault L, Cannon M, Murray R, Poulton R, Caspi A, Moffitt TE (2002). Cannabis use in adolescence and risk for adult psychosis : Longitudinal prospective study. British Medical Journal 325, 1212-1213.
2. Battisti RA, Roodenrys S, Johnstone SJ, Pesa N, Hermens DF, Solowij N (2010a). Chronic cannabis users show altered neurophysiological functioning on Stroop task conflict resolution. Psychopharmacology 212, 613-624.
3. Battisti RA, Roodenrys S, Johnstone SJ, Respondek C, Hermens DF, Solowij N (2010b). Chronic use of cannabis and poor neural efficiency in verbal memory ability. Psychopharmacology 209, 319-330.
4. Bhattacharyya S, Atakan Z, Martín-Santos R, Crippa JA, Kambeitz J, Prata D, Williams S, Brammer M, Collier DA, McGuire PK (2012a). Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis : AKT1 and DAT1 genotype modulates the effects of D-9- tetrahydrocannabinol on midbrain and striatal function. Molecular Psychiatry. Published online 31 January 2012. doi :10.1038/mp.2011.
5. Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J, OCarroll C, Seal ML, Giampietro V, Brammer M, Zuardi AW, Atakan Z, McGuire PK (2012b). Induction of psychosis by D9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry 69, 27-36.
6. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, OCarroll C, Allen P, Seal ML, Fletcher PC, Crippa JA, Giampietro V, Mechelli A, Atakan Z, McGuire P (2009). Modulation of mediotemporal and ventrostriatal function in humans by D9-tetrahydrocannabinol : A neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of General Psychiatry 66, 442-451.
7. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, OCarroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire P (2010). Opposite effects of D-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764-774.
8. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, Fraccaro V, Atakan Z, Martin-Santos R, OCarroll C, Rubia K, McGuire PK (2008). Neural basis of D-9-tetrahydrocannabinol and cannabidiol : Effects during response inhibition. Biological Psychiatry 64, 966-973.
9. Brammer MJ, Bullmore ET, Simmons A, Williams SCR, Grasby PM, Howard RJ, Woodruff PWR, Rabe-Hesketh S (1997). Generic brain activation mapping in fMRI: A non-parametric approach. Magnetic Resonance Imaging 15, 763-770.
10. Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ (1999). Global, voxel and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Transactions on Medical Imaging 18, 32-42.
11. Cascini F, Aiello C, Di Tanna G (2011). Increasing delta-9- tetrahydrocannabinol (D-9-THC) content in herbal cannabis over time : Systematic review and meta-analysis. Current Drug Abuse Reviews 5, 32-40.
12. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-Omethyltransferase gene: Longitudinal evidence of a gene r environment interaction. Biological Psychiatry 57, 1117-1127.
13. Chambers CD, Garavan, Bellgrove MA (2009). Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neuroscience and Biobehavioural Reviews 33, 631-646.
14. Chesher GB, Bird KD, Jackson DM, Perrignon A, Starmer GA (1990). The effects of orally administered delta 9-tetrahydrocannabinol in man on mood and performance measures: A dose-response study. Pharmacology, Biochemistry and Behavior 35, 861-864.
15. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J (2002). Cognitive subjective dose-response effects of acute oral D9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164, 61-70.
16. Degenhardt L, Coffey C, Carlin JB, Swift W, Moore E, Patton GC (2010). Outcomes of occasional cannabis use in adolescence : 10-year follow-up study in Victoria, Australia. British Journal of Psychiatry 196, 290-295.
17. DSouza DC, Perry E, MacDougall L, Ammerman Y, Cooper TB, Wu YT, Braley G, Gueorguieva R, Krystal JH (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals : Implications for psychosis. Neuropsychopharmacology 29, 1558-1572.
18. DSouza DC, Sewell RA, Ranganathan M (2009). Cannabis and psychosis/schizophrenia : Human studies. European Archives of Clinical Neurosciences 259, 413-431.
19. Enticott PG, Ogloff JR, Bradshaw JL (2008). Response inhibition and impulsivity in schizophrenia. Psychiatry Research 157, 251-254.
20. Fleck DE, Kotwal R, Eliassen JC, Lamy M, DelBello MP, Adler CM, Durling M, Cerullo MA, Strakowski SM (2011). Preliminary evidence for increased frontosubcortical activation on a motor impulsivity task in mixed episode bipolar disorder. Journal of Affective Disorders 133, 333-339.
21. Fusar-Poli P, Broome MR, Matthiasson P, Woolley JB, Johns LC, Tabraham P, Bramon E, Valmaggia L, William SC, McGuire P (2010). Spatial working memory in individuals at high risk for psychosis : Longitudinal fMRI study. Schizophrenia Research 123, 45-52.
22. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, OCarroll C, Atakan Z, Zuardi AW, McGuire PK (2009). Distinct effects of D9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry 66, 95-105.
23. Fusar-Poli P, Radua J, McGuire P, Borgwardt S (2011). Neuroanatomical maps of psychosis onset : Voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophrenia Bulletin. Published online 17 November 2011. doi :10.1093/schbul/sbr134.
24. Gray KM, Hart CL, Christie DK, Upadhyaya HP (2008). Tolerability and effects of oral D9-tetrahydrocannabinol in older adolescents with marijuana use disorders. Pharmacology, Biochemistry and Behavior 91, 67-70.
25. Green B, Kavanagh D, Young R (2003). Being stoned : A review of self-reported cannabis effects. Drug and Alcohol Review 22, 453-460.
26. Grotenhermen F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics 42, 327-360.
27. Gruber SA, Yurgelun-Todd DA (2005). Neuroimaging of marijuana smokers during inhibitory processing : A pilot investigation. Brain Research. Cognitive Brain Research 23, 107-118.
28. Hayasaka S, Nichols TE (2003). Validating cluster size inference : Random field and permutation methods. Neuroimage 20, 2343-2356.
29. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J (2004). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330, 11-14.
30. Hester R, Nestor L, Garavan H (2009). Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users. Neuropsychopharmacology 4, 2450-2458.
31. Honea R, Crow TJ, Passingham D, Mackay CE (2005). Regional deficits in brain volume in schizophrenia : A metaanalysis of voxel-based morphometry studies. American Journal of Psychiatry 162, 2233-2245.
32. Honey GD, Corlett PR, Absolam AR, Lee M, Pomarol-Clotet E, Murray GK, McKenna PJ, Bullmore ET, Menon DK, Fletcher PC (2008). Individual differences in psychotic effects of ketamine are predicted by brain function measure under placebo. Journal of Neuroscience 28, 6295-7303.
33. Huddy VC, Aron AR, Harrison M, Barnes TR, Robbins TW, Joyce EM (2009). Impaired conscious and preserved unconscious inhibitory processing in recent onset schizophrenia. Psychological Medicine 39, 907-916.
34. Hughes ME, Fulham WR, Johnston PK, Michie PT (2012). Stop-signal response inhibition in schizophrenia : Behavioural, event-related potential and functional neuroimaging data. Biological Psychiatry 89, 220-231.
35. Jardri R, Pouchet A, Pins D, Thomas P (2011). Cortical activations during auditory verbal hallucinations in schizophrenia : A coordinate-based meta-analysis. American Journal of Psychiatry 168, 73-81.
36. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
37. Kiehl KA, Smith AM, Hare RD, Liddle PF (2000). An event-related potential investigation of response inhibition in schizophrenia and psychopathy. Biological Psychiatry 48, 210-221.
38. Lemberger L, Axelrod J, Kopin IJ (1971). Metabolism disposition of D9-tetrahydrocannabinol in man. Pharmacological Review 23, 371-380.
39. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yucel M (2010). Structural MRI findings in long-term cannabis users : What do we knowSubstance Use and Misuse 45, 1787-1808.
40. Martin-Santos R, Fagundo AB, Crippa JA, Atakan Z, Bhattacharyya S, Allen P, Fusar-Poli P, Borgwardt S, Seal M, Busatto GF, McGuire P (2010). Neuroimaging in cannabis use : A systematic review of the literature. Psychological Medicine 40, 383-398.
41. Marvel CL, Turner BM, OLeary DS, Johnson HJ, Pierson RK, Pnoto LL, Andreasen NC (2007). The neural correlates of implicit sequence learning in schizophrenia. Neuropsychology 21, 761-777.
42. McDonald B, Highley JR, Walker MA, Herron BM, Cooper SJ, Esiri MM, Crow TJ (2000). Anomalous asymmetry of fusiform and parahippocampal gyrus gray matter in schizophrenia : A postmortem study. American Journal of Psychiatry 157, 40-47.
43. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM (1995). Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Research 15, 277-281.
44. Mechelli A, Fusar-Poli P, Papagni SA, Tognin S, Kambeitz J, Fu C, Picchioni M, Walshe M, Toulopoulou T, Bramon E, Murray R, McGuire P (2012). Genetic vulnerability to psychosis and cortical function : Epistatic effects between DAAO and G72. Current Pharmacological Design 18, 510-517.
45. Meijer JH, Schmitz N, Nieman DH, Becker HE, van Amelsvoort TA, Dingemans PM, Linszen DH, de Haan L (2011). Semantic fluency deficits and reduced grey matter before transition to psychosis : A voxelwise correlational analysis. Psychiatry Research 194, 1-6.
46. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370, 319-328.
47. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, MurrayRM (2009). The acute effects of synthetic intravenous D9- tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine 39, 1607-1616.
48. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980). Plasma delta-9 tetrahydrocannabinol concentrations clinical effects after oral intravenous administration smoking. Clinical Pharmacology and Therapeutics 28, 409-416.
49. Peters BD, de Koning P, Dingemans P, Becker H, Linszen DH, de Haan L (2009). Subjective effects of cannabis before the first psychotic episode. Australian and New Zealand Journal of Psychiatry 43, 1155-1162.
50. Rabe-Hesketh S, Bullmore ET, Brammer MJ (1997). The analysis of functional magnetic resonance images. Statistical Methods in Medical Research 6, 215-237.
51. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology 23, 266-277.
52. Roberts GM, Garavan H (2010). Evidence of increased activation underlying cognitive control in ecstasy and cannabis users. Neuroimage 15, 429-435.
53. Rubia K, Russell T, Bullmore ET, Soni W, Brammer MJ, Simmons A, Taylor E, Andrew C, Giampietro V, Sharma T (2001). An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function. Schizophrenia Research 52, 47-55.
54. Rubia K, Russell T, Overmeyer S, Brammer MJ, Bullmore ET, Sharma T, Simmons A, William SC, Giampetro V, Andrew CM, Taylor E (2001). Mapping motor inhibition : Conjunctive brain activations across different versions of go/no-go and stop tasks. Neuroimage 13, 250-261.
55. Rubia K, Smith AB, Brammer MJ, Taylor E (2007). Temporal lobe dysfunction in medication-naive boys with attentiondeficit/ hyperactivity disorder during attention allocation and its relation to response variability. Biological Psychiatry 62, 999-1006.
56. Simmonds DJ, Pekar JJ, Mostofsky SH (2008). Meta-analysis of go/no-go tasks demonstrating that fMRI activation associated with response inhibition task is task-dependent. Neuropsychologia 46, 224-232.
57. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, McGuire PK, Riecher-Rossler A, Borgwardt SJ (2010). Neuroimaging predictors of transition to psychosis -A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews 34, 1207-1222.
58. Stirling J, Barkus EJ, Nabosi L, Irshad S, Roemer G, Schreudergoidheijt B, Lewis S (2008). Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology 41, 371-378.
59. Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ, OGorman RL, McLean MA, Barker GJ, McGuire P (2010). Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biological Psychiatry 68, 599-602.
60. Tapert SF, Schweinsburg AD, Drummond SPA, Paulus MP, Brown SA, Yang TT, Frank LR (2007). Functional MRI of inhibitory processing in abstinent adolescent marijuana users. Psychopharmacology 194, 173-183.
61. Thirion B, Pinel P, Tucholka A, Roche A, Ciuciu P, Mangin JF, Poline JB (2007). Structural analysis of fMRI data revisited : Improving the sensitivity and reliability of fMRI group studies. IEEE Transactions on Medical Imaging 26, 1256-1269.
62. Thomas H (1996). A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence 42, 201-207.
63. Turken AU, Vuilleumier P, Mathalon DH, Swick D, Ford JM (2003). Are impairments of action monitoring and executive control true dissociative dysfunctions in patients with schizophrenia American Journal of Psychiatry 160, 1881-1883.
64. van Winkel R; Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011). Family-based analysis of genetic variation underlying psychosisinducing effects of cannabis : Sibling analysis and proband follow-up. Archives of General Psychiatry 68, 148-157.
65. Winton-Brown TT, Allen P, Bhattacharrya S, Borgwardt SJ, Fusar-Poli P, Crippa JA, Seal M, Martin-Santos R, Ffytche D, Zuardi AW, Atakan Z, McGuire PK (2011). Modulation of auditory and visual processing by delta-9- tetrahydrocannabinol and cannabidiol : An fMRI study. Neuropsychopharmacology 36, 1340-1348.
66. Witthaus H, Kaufmann C, Bohner G, Ozgurdal S, Gudlowski Y, Gallinat J, Ruhrmann S, Brune M, Heinz A, Klingebiel R, Juckel G (2009). Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Research 173, 163-169.
67. Wolf DH, Gur RC, Valdez JN, Loughead J, Elliott MA, Gur R, Ragland JD (2007). Alterations of fronto-temporal connectivity during word encoding in schizophrenia. Psychiatry Research 154, 221-232.
68. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. British Medical Journal 325, 1199-1201.